Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) Invested Capital (2017 - 2025)

Historic Invested Capital for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $1.1 billion.

  • Crinetics Pharmaceuticals' Invested Capital rose 2871.49% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 2871.49%. This contributed to the annual value of $1.3 billion for FY2024, which is 14574.11% up from last year.
  • As of Q3 2025, Crinetics Pharmaceuticals' Invested Capital stood at $1.1 billion, which was up 2871.49% from $1.2 billion recorded in Q2 2025.
  • Crinetics Pharmaceuticals' 5-year Invested Capital high stood at $1.3 billion for Q4 2024, and its period low was $149.5 million during Q1 2021.
  • Moreover, its 5-year median value for Invested Capital was $386.2 million (2022), whereas its average is $590.3 million.
  • Per our database at Business Quant, Crinetics Pharmaceuticals' Invested Capital crashed by 3419.5% in 2023 and then surged by 22692.27% in 2024.
  • Crinetics Pharmaceuticals' Invested Capital (Quarter) stood at $331.9 million in 2021, then fell by 4.7% to $316.3 million in 2022, then soared by 70.43% to $539.1 million in 2023, then skyrocketed by 145.74% to $1.3 billion in 2024, then fell by 19.07% to $1.1 billion in 2025.
  • Its Invested Capital was $1.1 billion in Q3 2025, compared to $1.2 billion in Q2 2025 and $1.3 billion in Q1 2025.